Extreme thrombocytopenia following abciximab therapy;Trombocitopenia extrema secundaria a abciximab

Revista Espanola de Cardiologia

Volumn 57, Issue 9, 2004, Pages 885-888

  Aragonés Manzanares, Rocío M ^a   Delgado Amaya, Manuel ^a   Bullones Ramírez, Juan A ^a   Prieto Palomino, Miguel A ^a   Arias García, Dolores M ^a   Castillo Castro, José L ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Abciximab; Angioplasty; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; THROMBOCYTE RECEPTOR; VON WILLEBRAND FACTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; HEART MUSCLE REVASCULARIZATION; HEMATOCRIT; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; FEMALE; HEART MUSCLE ISCHEMIA; METHODOLOGY; MIDDLE AGED; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 7044264652     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(04)77209-7     Document Type: Article

References (23)

1. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353:227-31.
2. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 1995;92:2373-80.
3. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
4. Makoni SN. Acute profound thrombocytopenia following angioplasty: the dilemma in the management and review of the literature. Heart 2001;86:E18.
5. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809-13.
6. Tcheng JE, Keriakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC. Abciximab readministration: results of the Reopro Readministration Registry. Circulation 2001;104:870-5.
7. Peter K, Straub A, Kohler B, Volkmann M, Scharz M, Kubler W, et al. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 1999;84:519-24.
8. Curtis BR, Swyers J, Divgi A, Mcfarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2000; 99:2054-9.
9. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352:87-92.
10. Hernández García JM, Domínguez Franco A, Jiménez-Navarro MF, Alonso Briales JH, Curiel Balsera E, Gó mez Doblas JJ, et al. ¿El abciximab mejora el pronóstico de los diabéticos tras la intervención coronaria percutánea? Rev Esp Cardiol 2002;55:810-5.
11. Keriakes DJ, Berkowitz SD, Lincoff AM, Tcheng JE, Wolski K, Achenbach R, et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 2000;140:74-80.
12. Reddy MS, Carmody TJ, Keriakes DJ. Severe delayed thrombocytopenia associated with abciximab (Reopro) therapy. Catheter Cardiovasc Interv 2001;52:486-8.
13. Vahdat B, Canavy I, Fourcade L, García E, Quilici J, Bonnet JL, et al. Fatal cerebral hemorraghe and severe thrombocytopenia during abciximab treatment. Catheter Cardiovasc Interv 2000;49: 177-80.
14. Jubelirer SJ, Koenig BA, Bates MC. Acute profound thrombocytopenia following c/E3 Fab (abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 1999;61:205-8.
15. Dasgupta H, Blankenship J, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J 2000;140:206-11.
16. Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP. Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996;78:1161-3.
17. Nguyen N, Salib H, Mascarenhas DA. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab. J Invasive Cardiol 2001;94:245-51.
18. Sane DC, Damaraju LV, Topol EJ, Cabot CF, Mascelli MA, Harrington RA, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000;36:75-83.
19. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci 1993;305: 208-15.
20. Galeote G, Hussein M, Sobrino N, Calvo L, Sánchez-Recalde A, Sobrino JA. Utilización de enoxaparina o heparina no fraccionada en combinación con abciximab durante la intervención coronaria percutánea: estudio piloto aleatorizado. Rev Esp Cardiol 2002;55: 1261-6.
21. Coto H. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab. J Invasive Cardiol 2000;12:528-31.
22. Tcheng JE, Keriakes DJ, Braden GA, Jordan RE, Mascelli MA, Langrall MA, et al. Readministration of abciximab: interim report of the Reopro readministration registry. Am Heart J 1999;138: S33-8.
23. Arjomand H, Magsi ZM, Chang KS, Mascarenhas DA. Abciximab readministration: a single-operator community-hospital experience. Catheter Cardiovasc Interv 1999;47:294-6.